BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24380373)

  • 1. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X; Cheong J; Ding X; Deshmukh G
    Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
    Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
    Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
    Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
    Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
    Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
    Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
    Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
    Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
    Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
    Doran AC; Osgood SM; Mancuso JY; Shaffer CL
    Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
    Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
    Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
    Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
    Shen DD; Artru AA; Adkison KK
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1825-57. PubMed ID: 15381336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
    Fujii S; Setoguchi C; Kawazu K; Hosoya K
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.
    Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
    Drug Metab Dispos; 2006 Sep; 34(9):1443-7. PubMed ID: 16760229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.
    Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A
    Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
    Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
    Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.